PMID- 9633901
OWN - NLM
STAT- MEDLINE
DCOM- 19980731
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 101
IP  - 3
DP  - 1998 Jun
TI  - Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in 
      patients with chronic myeloid leukaemia during interferon-alpha therapy.
PG  - 552-7
AB  - There is a need for fast and sensitive methods to evaluate the response of 
      patients with chronic myeloid leukaemia (CML) to interferon-alpha (IFN-alpha) 
      therapy to complement cytogenetic analysis of Philadelphia (Ph) 
      chromosome-positive metaphases. We have used interphase FISH (fluorescence in 
      situ hybridization) and competitive RT-PCR (reverse transcriptase-polymerase 
      chain reaction) techniques for detection of BCR-ABL-positive cells to measure 
      suppression of leukaemic clone in a series of 51 follow-up samples from 24 CML 
      patients undergoing IFN-alpha treatment. Interphase FISH analysis of the 
      malignant clone in bone marrow using BCR and ABL probes was found to be highly 
      correlated to conventional G-banding metaphase examination (r = 0.98). RT-PCR 
      quantification of BCR-ABL mRNA transcripts in blood also showed a high degree of 
      concordance with the proportion of Ph-positive metaphases (r = 0.93). In 
      addition, the degree of cytogenetic response did not influence the equivalence 
      between karyotype analysis and molecular methods. We concluded that interphase 
      FISH and competitive RT-PCR provide reliable information on residual tumour 
      burden and response to IFN-alpha in CML patients. These molecular methods may 
      significantly improve the efficiency of residual disease monitoring during 
      IFN-alpha therapy of CML.
FAU - Tchirkov, A
AU  - Tchirkov A
AD  - Laboratoire de Cytogenetique Medicale, Faculte de Medecine, Clermont-Ferrand, 
      France.
FAU - Giollant, M
AU  - Giollant M
FAU - Tavernier, F
AU  - Tavernier F
FAU - Briancon, G
AU  - Briancon G
FAU - Tournilhac, O
AU  - Tournilhac O
FAU - Kwiatkowski, F
AU  - Kwiatkowski F
FAU - Philippe, P
AU  - Philippe P
FAU - Choufi, B
AU  - Choufi B
FAU - Demeocq, F
AU  - Demeocq F
FAU - Travade, P
AU  - Travade P
FAU - Malet, P
AU  - Malet P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Female
MH  - Fusion Proteins, bcr-abl
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Interferon-alpha/*therapeutic use
MH  - Interphase
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology/*therapy
MH  - Leukemia, Myeloid, Accelerated Phase/pathology/therapy
MH  - Leukemia, Myeloid, Chronic-Phase/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Polymerase Chain Reaction/*methods
MH  - Prospective Studies
MH  - RNA, Messenger/analysis
MH  - Sensitivity and Specificity
EDAT- 1998/06/20 00:00
MHDA- 1998/06/20 00:01
CRDT- 1998/06/20 00:00
PHST- 1998/06/20 00:00 [pubmed]
PHST- 1998/06/20 00:01 [medline]
PHST- 1998/06/20 00:00 [entrez]
AID - 10.1046/j.1365-2141.1998.00717.x [doi]
PST - ppublish
SO  - Br J Haematol. 1998 Jun;101(3):552-7. doi: 10.1046/j.1365-2141.1998.00717.x.